Catalyst Wire Dossier Catalyst Wire Dossier

Toripalimab Injection (JS001)

toripalimab · Shanghai Junshi Bioscience Co., Ltd.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Toripalimab Injection (JS001), covering 2021-11-24 to 2021-11-24. Get the full timeline:

Most recent: Clinical Trial Update: A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC) [Phase 2]

See pricing